Mir-205 Acts As a Tumour Radiosensitizer by Targeting ZEB1 and Ubc13
Peijing Zhang,Li Wang,Cristian Rodriguez-Aguayo,Yuan,Bisrat G. Debeb,Dahu Chen,Yutong Sun,M. James You,Yongqing Liu,Douglas C. Dean,Wendy A. Woodward,Han Liang,Xianbin Yang,Gabriel Lopez-Berestein,Anil K. Sood,Ye Hu,K. Kian Ang,Junjie Chen,Li Ma
DOI: https://doi.org/10.1038/ncomms6671
IF: 16.6
2014-01-01
Nature Communications
Abstract:Tumour cells associated with therapy resistance (radioresistance and drug resistance) are likely to give rise to local recurrence and distant metastatic relapse. Recent studies revealed microRNA (miRNA)-mediated regulation of metastasis and epithelial-mesenchymal transition; however, whether specific miRNAs regulate tumour radioresistance and can be exploited as radiosensitizing agents remains unclear. Here we find that miR-205 promotes radiosensitivity and is downregulated in radioresistant subpopulations of breast cancer cells, and that loss of miR-205 is highly associated with poor distant relapse-free survival in breast cancer patients. Notably, therapeutic delivery of miR-205 mimics via nanoliposomes can sensitize the tumour to radiation in a xenograft model. Mechanistically, radiation suppresses miR-205 expression through ataxia telangiectasia mutated (ATM) and zinc finger E-box binding homeobox 1 (ZEB1). Moreover, miR-205 inhibits DNA damage repair by targeting ZEB1 and the ubiquitin-conjugating enzyme Ubc13. These findings identify miR-205 as a radiosensitizing miRNA and reveal a new therapeutic strategy for radioresistant tumours.